肝功能不全患者治疗酒精戒断综合征时是否应避免使用氯氮卓和地西泮
本文为综述性文章,探讨肝功能不全患者治疗酒精戒断综合征时氯氮卓与地西泮的取舍。作者分析认为,氯氮卓本身镇静活性极低,主要依赖肝氧化代谢为活性代谢物(如去甲西泮,半衰期14-95 h),肝功能不全时代谢延迟可致「剂量堆积」,产生延迟、深重且持久的镇静。地西泮主要代谢物去甲西泮镇静活性不高于地西泮本身,地西泮静脉给药5 min内、口服120 min内达峰,肝功能不全不影响其快速起效,便于滴定。作者结论认为地西泮在给药间隔超过达峰时间且每次给药前评估镇静的前提下可用于肝功能不全患者,而氯氮卓即使密切监测也可能因未被识别的剂量堆积导致镇静延长。
要点
- 氯氮卓本身镇静活性极低,其效应主要依赖肝氧化生成的代谢物,肝功能不全时生物转化显著延迟。
- 氯氮卓代谢物去甲西泮半衰期为14-95 h,明显长于氯氮卓的6.6-28 h,肝功能不全时可能进一步延长。
- 肝功能不全患者使用氯氮卓可能发生「剂量堆积」,导致延迟、深重且持久的镇静。
- 地西泮静脉给药5 min内达峰、口服120 min内达峰,肝功能不全不影响其快速起效,便于滴定。
- 作者认为肝功能不全患者使用地西泮时,给药间隔应超过达峰时间,且每次给药前评估镇静程度,这些措施可纳入前负荷给药和症状触发治疗方案。
适用人群与场景
- 肝功能不全合并酒精戒断综合征、需要苯二氮卓类药物治疗的患者。
处置流程与药物剂量
- 作者认为肝功能不全患者使用地西泮时,给药间隔应超过其达峰时间(静脉给药5 min内达峰,口服120 min内达峰),且每次给药前评估镇静程度。
- 作者认为上述给药间隔超过达峰时间及每次给药前评估镇静的措施,可纳入前负荷给药和症状触发治疗方案。
- 作者认为氯氮卓在肝功能不全患者中即使密切监测也可能因未被识别的剂量堆积导致镇静延长。
研究设计与关键结果
- 本文为综述,作者分析认为氯氮卓的镇静效应主要依赖其代谢物,肝氧化代谢在肝功能不全时显著延迟,可能导致剂量堆积。
- 氯氮卓代谢物去甲西泮半衰期为14-95 h,氯氮卓半衰期为6.6-28 h,肝功能不全时两者半衰期可能进一步延长。
- 地西泮主要代谢物去甲西泮镇静活性不高于地西泮本身,地西泮静脉给药5 min内达峰、口服120 min内达峰,肝功能不全不影响其快速起效。
- 作者认为氯氮卓导致镇静延长的风险主要来自起效和达峰延迟驱动的剂量堆积,而非单纯半衰期延长。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肝功能不全患者可使用地西泮治疗酒精戒断,但给药间隔须超过达峰时间,且每次给药前评估镇静程度。
- 作者认为氯氮卓在肝功能不全患者中可能因剂量堆积导致镇静延长,即使密切监测也难以避免。
- 作者指出,长期推荐肝功能不全患者避免使用地西泮的观点,其依据可能不正确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Chlordiazepoxide and diazepam are first-line treatments for patients with alcohol withdrawal. However, their use is discouraged in hepatic insufficiency due to concerns that impaired metabolism may prolong their half-lives and those of their active metabolites, increasing the risk of prolonged sedation to an unacceptable level.
THE ACTIVITY OF CHLORDIAZEPOXIDE AND ITS METABOLITES: Findings presented here suggest that chlordiazepoxide has minimal sedative activity-its effect is primarily dependent on its metabolites. Chlordiazepoxide metabolism occurs through hepatic oxidation, so its biotransformation to its metabolites can be markedly delayed in patients with hepatic insufficiency. Because unmetabolized chlordiazepoxide has little activity, this delay may lead to the administration of a considerable cumulative dose before a therapeutic response occurs. This could result in the accumulation of a substantial reservoir of unmetabolized chlordiazepoxide ("dose-stacking"). This reservoir would undergo slow biotransformation to chlordiazepoxide metabolites, even after dosing is discontinued. The chlordiazepoxide metabolite demoxepam has a markedly longer half-life (14-95 h) than chlordiazepoxide (6.6-28 h), which may be further prolonged by hepatic insufficiency. Therefore, if chlordiazepoxide dose-stacking occurs in patients with hepatic insufficiency, demoxepam may also accumulate. This can result in a delayed, profound, and prolonged sedative effect.
THE ACTIVITY OF DIAZEPAM AND ITS MAJOR METABOLITE: The major metabolite of diazepam, desmethyldiazepam, is no more sedating than diazepam itself. As a result, the rapid onset sedative effect of diazepam-reaching its peak within 5 min when administered intravenously and within 120 min when administered orally-is unaffected by hepatic insufficiency. This allows accurate titration of diazepam to avoid prolonged sedation, even with compromised liver function.
DISCUSSION: The widely accepted assertion that the increased risk of prolonged sedation when using chlordiazepoxide to treat alcohol withdrawal in patients with hepatic insufficiency is primarily due to the prolonged half-lives of chlordiazepoxide and its metabolites appears incorrect. It primarily results from a delayed onset of action and peak effect, driven by slowed chlordiazepoxide metabolism and the greater activity of its metabolites compared to the parent drug. These factors combine to increase the risk of dose-stacking. Dose-stacking is readily avoided with diazepam use in patients with hepatic insufficiency because its rapid time-to-peak effect is unaffected.
CONCLUSIONS: Although it has long been recommended that diazepam be avoided for the treatment of alcohol withdrawal in patients with hepatic insufficiency, the findings presented here suggest that it can be used as long as the dosing interval exceeds the time-to-peak effect and the patient is assessed for sedation before each dose-measures incorporated into front-loading and symptom-triggered treatments. In contrast, chlordiazepoxide may cause prolonged sedation in patients with hepatic insufficiency-even with close monitoring-due to unrecognized dose-stacking.
参考来源
- Weintraub SJ. Should chlordiazepoxide and diazepam be avoided when treating alcohol withdrawal syndrome in patients with hepatic insufficiency? Clin Toxicol (Phila). 2025. PMID: 40445132. doi:10.1080/15563650.2025.2493216
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。